Xeris expands board to 9, appoints Ricki Fairley as Class III director

Xeris Biopharma Holdings, Inc.

Ricki Fairley appointed to board on March 27, 2023, expanding board from 8 to 9 members.
Fairley brings 35+ years of marketing experience; currently CEO of TOUCH, The Black Breast Cancer Alliance.
Received 85,000 RSUs vesting in equal annual installments over three years.
Fairley's compensation follows the Non-Employee Director Compensation Policy filed as Exhibit 10.1.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Ricki Fairley

Director

XERS · Xeris Biopharma Holdings, Inc.

Effective: 2023-03-27
Filed: March 29, 2023, 7:59 PM ET

On March 29, 2023, Xeris Biopharma Holdings, Inc. (the “Company”) announced the expansion of the Company’s Board of Directors (the "Board") from 8 to 9 members and the appointment of Ricki Fairley to the Board on March 27, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ricki Fairley was appointed as Director at Xeris Biopharma Holdings, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 29, 2023, Xeris Biopharma Holdings, Inc. (the “Company”) announced the expansion of the Company’s Board of Directors (the "Board") from 8 to 9 members and the appointment of Ricki Fairley to the Board on March 27, 2023.

View on SEC.gov

Xeris Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001867096-23-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.